Recent Research Analysts’ Ratings Changes for RadNet (RDNT)

Several analysts have recently updated their ratings and price targets for RadNet (NASDAQ: RDNT):

• 8/28/2026 – RadNet had its price target raised by Barclays PLC from $65.00 to $79.00. They now have an “overweight” rating on the stock.
• 8/13/2026 – RadNet was upgraded by Zacks Research from “strong sell” to “hold”.
• 8/11/2026 – RadNet had its price target raised by Truist Financial Corporation from $90.00 to $94.00. They now have a “buy” rating on the stock.
• 8/7/2026 – RadNet had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/31/2026 – RadNet had its “buy” rating reaffirmed by Jefferies Financial Group Inc..
• 7/13/2026 – RadNet was downgraded by Zacks Research from “hold” to “strong sell”.

Insider Activity

In other RadNet news, Director David L. Swartz sold 2,699 shares of the business’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $53.89, for a total value of $145,449.11. Following the completion of the transaction, the director directly owned 177,013 shares of the company’s stock, valued at approximately $9,539,230.57. The trade was a 1.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Cornelis Wesdorp sold 4,750 shares of the business’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $58.11, for a total value of $276,022.50. Following the completion of the transaction, the chief executive officer directly owned 69,075 shares of the company’s stock, valued at approximately $4,013,948.25. The trade was a 6.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 5.14% of the company’s stock.

RadNet, Inc is a leading independent provider of outpatient diagnostic imaging services in the United States. Through a nationwide network of fixed-site imaging centers and affiliated joint-venture locations, the company delivers a comprehensive suite of radiology services including MRI, CT, PET/CT, ultrasound, X-ray, mammography, bone densitometry, nuclear medicine and interventional radiology procedures. RadNet also offers teleradiology and imaging management solutions to physician practices, hospitals and healthcare systems.

Founded in 1981 and headquartered in Los Angeles, RadNet has expanded its footprint organically and through strategic acquisitions.